A5032218366- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Pharmacology and Obesity Treatment
- Diabetes Treatment and Management
- Liver Disease Diagnosis and Treatment
- Electrolyte and hormonal disorders
- Potassium and Related Disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Metabolism, Diabetes, and Cancer
- Lipid metabolism and disorders
- Diet and metabolism studies
- Pharmaceutical Economics and Policy
- Ion Transport and Channel Regulation
- Cholesterol and Lipid Metabolism
- Diet, Metabolism, and Disease
- Renal function and acid-base balance
- Antiplatelet Therapy and Cardiovascular Diseases
- Paraoxonase enzyme and polymorphisms
- Folate and B Vitamins Research
- COVID-19 Clinical Research Studies
- Peroxisome Proliferator-Activated Receptors
- Diabetes Management and Research
- Cardiovascular Disease and Adiposity
- Muscle metabolism and nutrition
University of Crete
2018-2025
University of Ioannina
2012-2025
University Hospital of Heraklion
2018-2024
Drexel University
2019
Mustansiriyah University
2019
SUNY Downstate Health Sciences University
2019
King Abdullah International Medical Research Center
2019
Multidisciplinary Digital Publishing Institute (Switzerland)
2019
Délégation Paris 5
2019
Yan'an Hospital Affiliated To Kunming Medical University
2017
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis treatment is paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines Hellenic Atherosclerosis Society focus on assessment risk, laboratory evaluation dyslipidemias, new emerging lipid-lowering drugs, as well lipid disorders in women, elderly patients with familial...
Recent clinical studies showed that lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a predictor for incident atherosclerotic disease. We have previously shown among the LDL subfractions, Lp-PLA(2) activity preferentially associated with atherogenic small, dense (sdLDL) particles in vitro. investigated whether could be marker of sdLDL human plasma.One hundred and seventy-six individuals participated study. subclass analysis was performed by polyacrylamide gel electrophoresis. mass...
Background: Recent studies suggest that the distribution of lipoprotein subfractions is an independent predictor vascular events. Therefore, we evaluated effect ezetimibe (a selective cholesterol transport inhibitor) on concentrations in patients with primary dyslipidaemia.Materials and methods: Patients (n = 50) dyslipidaemias were recruited. The individual measured using Lipoprint system at baseline after 16 weeks treatment.Results: Ezetimibe reduced total, low-density (LDL‑C)...